Live
FierceBiotechASCO, Ryght AI team up for breast cancer trial site selectionClinical OMICsPancreatic Cancer Drug Doubles Survival While Reducing Side EffectsEndpoints NewsShionogi wins US approval for first pill to prevent Covid following exposureEndpoints News#ASCO: Lilly's plenaries; Incyte's frontline data in lymphomaBioPharma DiveServier buys into muscular dystrophy with potentially $2.7B dealBioWorldASCO 2026: A revolution in pancreatic cancerBioWorldBiggest gainers and losers for May 25-29, 2026Endpoints NewsAgios licenses Oscotec drug; CEPI funds three potential Ebola vaccinesPromega BlogAdvancing Canine Cancer Immunotherapy through One Health Comparative Oncology ResearchEndpoints News#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T updateEndpoints NewsAfter being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listingFierceBiotechRallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
This story is not available in the archive.